A renaissance for SRC
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that SRC activation may also be a dominant feature in CRC, which is supported by the observation that SRC activation was documented in > 80% of CRC [17].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“In response signaling from a variety of RTKs (including EGFR, HER2, HER4, PDGFR, VEGFR, FGFR4, GPCR, C-MET, IL-4/IL13/IL-13Rα2, IL-6ST/IL-6R/IL-11R), SRC has been reported to mediate diverse cell signaling pathways including RAS/MAPK (proliferation), PI3K/AKT (survival), FAK (adhesion/migration/EMT), and STAT3 (angiogenesis) [17, 49, 50].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“Aberrant SRC activation has been associated with a more aggressive phenotype and a worse prognosis in CRC patients [27, 28, 39].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [39]
In the citing paper
“The c-src is a non-receptor protein tyrosine kinase with a 60-kD molecular weight.It is a member of a 9-gene family named the Src family kinases (SFKs)”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [1]
Citations
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859 · cited 1×
“Focal adhesions are also disassembled during transformation, during which the integrity of these structures is disrupted, permitting increased motilit”
BackgroundCell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915 · cited 1×
“This is followed by release of adhesions and retraction of the rear en”
BackgroundGiancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345 · cited 1×
“Although not yet reported for c- SRC , it has been possible to transform human fibroblasts with oncogenes such as HRAS when they are combined with human telomerase reverse transcriptase and the SV40 large T antige”
BackgroundTransforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332 · cited 1×
“v- src was subsequently shown to encode a tyrosine-specific protein kinas”
BackgroundThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STAT3 activation by v-Src has also been shown to contribute to other biological properties of cancer cells, including cell growth and survival, and tumour-cell immune evasio”
BackgroundFOCAL ADHESIONS, CONTRACTILITY, AND SIGNALING
Burridge, K., & Chrzanowska-Wodnicka, M. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.463 · Cited by 1,942 · cited 1×
“Small adhesions can transmit stong forces for rapid movement and ultimately mature into larger focal adhesion”
BackgroundReduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice
llić, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., et al. (1995) · Nature · doi:10.1038/377539a0 · Cited by 1,830
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.
Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D., & Birchmeier, W. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.1.173 · Cited by 1,551 · cited 1×
“Definitive studies in transgenic mice indicate that E-cadherin is an invasion suppresso”
BackgroundA causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,424 · cited 1×
“and overexpression of E-cadherin can, in fact, counteract the acquisition of the invasive phenotyp”
Background
Cited by
Items 701–800 of 999
Sosa, A. C. B., Boschelli, D. H., Wu, B., Wang, Y., & Golas, J. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.004 · Cited by 19
Src family kinase inhibitor PP2 accelerates differentiation in human intestinal epithelial cells
Seltana, A., Guezguez, A., Lepage, M., Basora, N., & Beaulieu, J. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.085 · Cited by 22
“Among these, Src, Fyn and Yes are ubiquitously expressed, whereas the others are expressed mainly in the immune system [2].”
BackgroundRNA codon expansion via programmable pseudouridine editing and decoding
Liu, J., Yan, X., Wu, H., Ji, Z., Shan, Y., Wang, X., Ran, Y., Ma, Y., Li, C., Zhu, Y., et al. (2025) · Nature · doi:10.1038/s41586-025-09165-x · Cited by 19
Poon, C. L. C., Brumby, A. M., & Richardson, H. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061585 · Cited by 20
Regulation of Src tumor activity by its N-terminal intrinsically disordered region
Aponte, E., Lafitte, M., Sirvent, A., Simon, V., Barbery, M., Fourgous, E., Boublik, Y., Maffei, M., Armand, F., Hamelin, R., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02092-x · Cited by 18
“INTRODUCTION Src, originally identified as an oncogene, is a membrane-anchored tyrosine kinase, which mediates signaling induced by a wide range of cell surface receptors, leading to cell growth and adhesion [1].”
BackgroundYakymovych, I., Yakymovych, M., Hamidi, A., Landström, M., & Heldin, C. (2022) · Science Signaling · doi:10.1126/scisignal.abp9521 · Cited by 21
“The mechanism that we describe has similarities to the well-established manner in which tyrosine kinase receptors activate Src, specifically through the binding of the Src SH2 domain to phosphorylated tyrosine residues in the receptors, whereafter the catalytic site of Src is opened (11, 17).”
BackgroundComparative Analysis of Dasatinib Effect between 2D and 3D Tumor Cell Cultures
Sabetta, S., Vecchiotti, D., Clementi, L., Nolfi, M. D. V., Zazzeroni, F., & Angelucci, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020372 · Cited by 21
“Src, therefore, not only promotes cancer cell growth but is also involved in the control of adhesiveness and migration, functioning as a key molecule that regulates signal transduction pathways triggered by various surface molecules, such as growth factor receptors and integrins [2,7].”
BackgroundThe ErbB Signaling Network and Its Potential Role in Endometrial Cancer
Georgios, A., Styliara, I., Zarogianni, E., Lazurko, N., Valasoulis, G., Michail, G., & Adonakis, G. (2023) · Epigenomes · doi:10.3390/epigenomes7040024 · Cited by 22
“Overall, the Src kinase pathway is implicated in many cellular processes and plays an important role in carcinogenesis [63,91,96,97].”
BackgroundMezquita, B., Mezquita, P., Pau, M., Mezquita, J., & Mezquita, C. (2014) · Cells · doi:10.3390/cells3010092 · Cited by 22
“The Src protein is composed of seven domains [38,44,45] (Figure 3): (1) An N-terminal region, which contains a myristoylation sequence, which is essential for binding to the inner surface of the cell membrane.”
BackgroundPediatric developmental therapies: Interesting new drugs now in early-stage clinical trials
Macy, M. E., Sawczyn, K. K., Garrington, T. P., Graham, D. K., & Gore, L. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0073-0 · Cited by 19
“[16, 17] Dasatinib, which is much more potent than imatinib against Abl, also inhibits Src, a non receptor tyrosine kinase, with a low nM IC50, compared to the μM IC50 of imatinib for Src.”
BackgroundKopetz, S., Morris, V. K., Parikh, N. U., Overman, M. J., Jiang, Z.-Q., Maru, D. M., Elvin, P., & Gallick, G. E. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-660 · Cited by 19
“In colorectal cancer, overexpression of the Src protein and epigenetic changes in the tumor cell have been correlated with increased activity of Src kinase [3,8], which clinically has been associated with shorter disease-free survival in patients undergoing curative resection and with shorter overall survival in patie…”
BackgroundChen, F., Yang, D., Wang, S., Che, X., Wang, J., Li, X., Zhang, Z., Chen, X., & Song, X. (2012) · IUBMB Life · doi:10.1002/iub.606 · Cited by 20
“C: Western blots were used to examine the expression of p-FAK, p-Src, pAkt, and pERK after 48 H in transfected PC-3 cells; only p-FAK and p-Src expression were decreased when compared with siRNA-NC (P \ 0.05).”
InfluentialTargeting lymphatic vessel functions through tyrosine kinases
Williams, S. P., Karnezis, T., Achen, M. G., & Stacker, S. A. (2010) · Vascular Cell · doi:10.1186/2040-2384-2-13 · Cited by 19
“Substrates are often activators or adaptors for cytosolic tyrosine kinases, such as the Src family kinases [24,25] which are directly involved in stimulus-induced signal transduction cascades.”
c-Src–Dependent and –Independent Functions of Matk in Osteoclasts and Osteoblasts
Kim, J. H., Kim, K., Kim, I., Seong, S., & Kim, N. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700582 · Cited by 19
“c-Src is a proto-oncogene that plays important roles in cell survival, growth, and proliferation (7, 8).”
BackgroundDasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
Al‐Asmakh, M., Bawadi, H. A., Hamdan, M. M., Gupta, I., Kheraldine, H., Jabeen, A., Rizeq, B. R., & Moustafa, A. A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111134 · Cited by 20
Nishida, H., Okada, M., Yang, L., Takano, T., Tabata, S., Soga, T., Ho, D. M., Chung, J., Minami, Y., & Yoo, S. K. (2021) · eLife · doi:10.7554/elife.59809 · Cited by 18
Virdee, S., Macmillan, D., & Waksman, G. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.01.015 · Cited by 18
Bcr interferes with β‐catenin–Tcf1 interaction
Reß, A., & Moelling, K. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.01.034 · Cited by 18
“of cells, to reduce cell adhesion, and to augment metastatic potential of cells [26,27].”
BackgroundIndovina, P., Casini, N., Forte, I. M., Garofano, T., Cesari, D., Iannuzzi, C. A., Porro, L. D., Pentimalli, F., Napoliello, L., Boffo, S., et al. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25397 · Cited by 18
“SFKs, whose aberrant activation is implicated in the onset and progression of many human cancers, are among the most promising targets for cancer therapy (Yeatman, 2004).”
Qin, Y., Wang, F., Miao, Y., Wu, X., Bai, M., Xi, X., & Feng, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5095-x · Cited by 18
TWEAK promotes hepatic stellate cell migration through activating EGFR/Src and PI3K/AKT pathways
Zhang, F., Xu, M., Yin, X., Guo, H., Zhang, B., Wang, Y., Xiao, J., Zou, X., Zhang, M., & Zhuge, Y. (2019) · Cell Biology International · doi:10.1002/cbin.11230 · Cited by 17
“Although EGFR activated multiple signaling pathways, the activation of Src, a non‐receptor tyrosine kinase that was functionally integrated into various signaling cascades and causally linked to tumor growth and metastasis, was a particularly critical signaling event (Yeatman, 2004; Zhang and Yu, 2012).”
Vielreicher, M., Harms, G. S., Butt, E., Walter, U., & Obergfell, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704107200 · Cited by 18
Koga, S., Yogo, K., Yoshikawa, K., Samori, H., Goto, M., Uchida, T., Ishida, N., & Takeya, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502703200 · Cited by 18
Cheng, H., Chong, Y., Ia, K. K., Tan, O., & Mulhern, T. D. (2006) · AfCS-Nature Molecule Pages · doi:10.1038/mp.a000705.01 · Cited by 17
Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities
Dang, X., Duan, J., Ye, E., Mao, N.-D., Bai, R., Zhou, X., & Ye, X. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106934 · Cited by 24
Exploring the Therapeutic Effects of Atractylodes macrocephala Koidz against Human Gastric Cancer
Choi, N.-R., Choi, W.-G., Zhu, A., Park, J., Kim, Y. T., Hong, J., & Kim, B.-J. (2024) · Nutrients · doi:10.3390/nu16070965 · Cited by 18
“SRC has been involved in the growth and metastasis of cancer cells and is also an important target for gastric cancer treatment [28]. c-SRC was the first oncogene discovered and has increased expression in gastric cancer [29,30].”
BackgroundKim, M., Lim, D. Y., Kim, J., Chen, H., Lubet, R. A., Dong, Z., & Bode, A. M. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22232 · Cited by 19
“Over the years, many reports have supported a key role of Src in various important cellular pathways, such as proliferation, differentiation, survival, metastasis, and angiogenesis [31,32].”
BackgroundMolecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors
Capdevila, J., & Salazar, R. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0128-7 · Cited by 17
“In vitro observations have led to the hypothesis that in addition to increasing cellular proliferation, a primary role for c-src in cancer is to regulate cell adhesion, invasion, and motility [62].”
BackgroundKoudelková, L., Pataki, A. C., Tolde, O., Pavlík, V., Nobis, M., Gemperle, J., Anderson, K. I., Brábek, J., & Rösel, D. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.024 · Cited by 17
Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells
Dosch, A. R., Dai, X., Gaidarski, A. A., Shi, C., Castellanos, J. A., VanSaun, M. N., Merchant, N. B., & Nagathihalli, N. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26621 · Cited by 18
Dai, F., Chen, Y., Huang, L., Wang, J., Zhang, T., Li, J., Tong, W., Liu, M., & Yi, Z. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12450 · Cited by 18
“Localization of FAK into adhesions induces its phosphorylation at Tyr397 and subsequently phosphorylation of c-Src and paxillin which also play an important role in focal adhesions [10, 47, 48].”
BackgroundProtein kinase inhibitors against malignant lymphoma
D’Cruz, O. J., & Uckun, F. M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.780031 · Cited by 18
“5 Src family kinase inhibitors The Src family kinases (SFKs) are the largest family of nonreceptor TKs (NRTK) and one of the best-studied targets for cancer therapy [64,65].”
Tsai, P., Chu, C., Fu, Y., Tseng, C.-H., Chen, Y., Chang, L., & Lin, S. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1875-4 · Cited by 17
Park, N., Park, Y. K., Yadav, A. K., Shin, Y., Bishop‐Bailey, D., Choi, J., Park, J. W., & Jang, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16782 · Cited by 17
Boschelli, D. H., Wu, B., Sosa, A. C. B., Chen, J. J., Golas, J. M., & Boschelli, F. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.07.061 · Cited by 17
O’Brian, C. A., Chu, F., Bornmann, W. G., & Maxwell, D. S. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.2.175 · Cited by 17
“82 Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.”
BackgroundSu, Y., Zhu, K., Wang, J., Liu, B., Chang, Y., Chang, D., & You, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117369 · Cited by 23
Headway in resistance to endocrine therapy in breast cancer.
Xu, Y., & Sun, Q. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.02.03.9 · Cited by 16
Hermida‐Prado, F., Granda‐Díaz, R., Del-Río-Ibisate, N., Villaronga, M. Á., Allonca, E., Garmendia, I., Montuenga, L. M., Rodríguez, R., Vallina, A., Álvarez‐Marcos, C., et al. (2019) · Cancers · doi:10.3390/cancers11111644 · Cited by 20
“SRC belongs to the highly conserved family of non-receptor protein tyrosine kinases known as the Src family kinases (SFKs) that includes SRC, BLK, FGR, FRK, FYN, HCK, LCK, LYN, YES, and YRK [3,4].”
BackgroundDustin, C. M., Habibovic, A., Hristova, M., Schiffers, C., Morris, C. R., Lin, M.-C. J., Bauer, R. A., Heppner, D. E., Daphtary, N., Aliyeva, M., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000995 · Cited by 17
Functional antibody delivery: Advances in cellular manipulation
Koch, K. C., & Tew, G. N. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114586 · Cited by 17
Loss of cell–cell adhesion triggers cell migration through Rac1-dependent ROS generation
Chen, Y., Hsu, J., Chu, C., Chang, Y.-W., Fan, J. C., Yang, M., & Chen, H. (2022) · Life Science Alliance · doi:10.26508/lsa.202201529 · Cited by 19
“Src, a non-receptor protein tyrosine kinase, has been shown to play crucial roles in a variety of cellular functions (Martin, 2001; Yeatman, 2004).”
BackgroundAwaji, A. A., Zaloa, W. A. Z. E., Seleem, M. A., Alswah, M., Elsebaei, M. M., Bayoumi, A. H., El-morsy, A., Alfaifi, M. Y., Shati, A. A., Elbehairi, S. E. I., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107228 · Cited by 16
Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
Inoue, T., & Ogawa, O. (2011) · Prostate Cancer · doi:10.1155/2011/647987 · Cited by 18
“The activation of Src kinase contributes to prostate carcinogenesis through activation of various signaling pathways, including RAS, PI3K-Akt, integrin-FAK, MAPK, and STAT3 signaling [51].”
BackgroundMorii, M., Kubota, S., Honda, T., Yuki, R., Morinaga, T., Kuga, T., Tomonaga, T., Yamaguchi, N., & Yamaguchi, N. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753202 · Cited by 22
Thiazoles in Peptides and Peptidomimetics
Mak, J. Y. W., Xu, W., & Fairlie, D. P. (2015) · Topics in heterocyclic chemistry · doi:10.1007/7081_2015_176 · Cited by 16
Src Kinase Regulation in Progressively Invasive Cancer
Xu, W., Allbritton, N. L., & Lawrence, D. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048867 · Cited by 22
“Src phosphorylation of caspase 8 is antiapoptotic [17] whereas Src-mediated STAT activation promotes cell growth and survival [9].”
BackgroundSrc-stimulated IRTKS phosphorylation enhances cell migration
Chen, G., Li, T., Zhang, L., Yi, M., Chen, F., Wang, Z., & Zhang, X. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.005 · Cited by 16
“The protein tyrosine kinase Src catalyzes the transfer of the terminal phosphate group of ATP to specific tyrosine residues present on protein substrates, and thereby transfers signals downstream of a variety of cell surface receptors, including integrins and RTKs [19].”
BackgroundXiao, X., Li, N., Zhang, D., Yang, B. K., Guo, H., & Li, Y. (2016) · Cellular Reprogramming · doi:10.1089/cell.2016.0020 · Cited by 17
“Pan-Src family kinase inhibitors src family kinases (SFKs) are a class of proto-oncogene tyrosine kinases that include c-Src, Yes, Fyn, Fgr, Lck, Hck, Blk, Lyn, and Frk in mammals (Yeatman, 2004).”
Delineating v-Src downstream effector pathways in transformed myoblasts
Ciuffini, L., Castellani, L., Salvati, E., Galletti, S., Falcone, G., & Alemà, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210665 · Cited by 16
“Therefore, information obtained from studies on v-Src transformation in vitro can shed light on the role of c-Src in cancer (Martin, 2001; Frame, 2002; Yeatman, 2004).”
BackgroundNautiyal, J., Yu, Y., Aboukameel, A., Kanwar, S. S., Das, J., Du, J., Patel, B. B., Sarkar, F. H., Rishi, A. K., Mohammad, R. M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0019 · Cited by 19
Androgen receptor regulates SRC expression through microRNA-203
Siu, M. K., Chen, W., Tsai, H., Yeh, H.-L., Yin, J. J., Liu, S.-Y., & Liu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8366 · Cited by 18
“SRC kinase also regulates numerous cell-signaling pathways that are important for cancer cell survival, proliferation, invasion, migration, and angiogenesis [6, 7].”
Ikeda, K., Nakayama, Y., Mayuko, I., Obata, Y., Kasahara, K., Fukumoto, Y., & Yamaguchi, N. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.009 · Cited by 15
“Overexpression and enhanced activity of Src-family kinases found in a large number of human malignancies have been linked to the development of cancer and progression to metastases [2,3], and there has recently been a renewed interest in Src-family kinases as molecular targets for cancer therapy [4].”
BackgroundCunnick, J. M., Kim, S., Hadsell, J., Collins, S. J., Cerra, C., Reiser, P., Flynn, D. C., & Cho, Y. H. (2014) · Oncogene · doi:10.1038/onc.2014.205 · Cited by 15
“To determine the response of AFAP1 to prolactin, we utilized the T47D mammary epithelial cell line known for its high PrlR level (17) and its requirement for cSrc in the prolactin response (27, 33, 34).”
Roux, A. L., Castro, B., Garbacik, E. T., Parajo, M. F. G., & Pons, M. (2016) · ChemistrySelect · doi:10.1002/slct.201600117 · Cited by 15
Aleem, S. U., Georghiou, G. P., Kleiner, R. E., Guja, K. E., Craddock, B. P., Lyczek, A., Chan, A. I., García–Díaz, M., Miller, W. T., Liu, D. R., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.07.017 · Cited by 15
“Src kinase, the prototypical SFK, is overexpressed or constitutively activated in many solid tumors types (Summy and Gallick, 2003; Yeatman, 2004) and inhibition of Src decreases metastasis and tumor growth in both cellular and animal cancer models.”
Nogueira, T. C. M., & Souza, M. V. N. D. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116340 · Cited by 16
Zhang, J., Zhao, D., Zhang, L., Xiao, Y., Wu, Q., Wang, Y., Chen, J., & Zhan, Q. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2216-x · Cited by 15
“Previous studies have shown that Src facilitates tumor proliferation, adhesion, invasion, or motility and regulates the cell plasticity of tumor cells by interacting and activating several substrate proteins (Irby and Yeatman, 2000; Roskoski, 2004; Yeatman, 2004).”
BackgroundCurrent Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Schenone, S., Zanoli, S., Brullo, C., Crespan, E., & Maga, G. (2008) · Current Drug Therapy · doi:10.2174/157488508785747862 · Cited by 16
McKinley, E. T., Liu, H., McDonald, W. H., Luo, W., Zhao, P., Coffey, R. J., Hanks, S. K., & Manning, H. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080207 · Cited by 19
“therapeutic target in CRC and other cancers [18-21].”
BackgroundSegarra, M., Lozano, E., Corbera‐Bellalta, M., Vilardell, C. P., Cibeira, M. T., Esparza, J., Izco, N., Bladé, J., & Cid, M. C. (2009) · Haematologica · doi:10.3324/haematol.2009.006395 · Cited by 15
“Fibronectin-induced Src activation was decreased by thalidomide as illustrated by the decrease in Src phosphorylation at Y416 elicited by thalidomide treatment (Figure 4A).(25) In contrast, Src phosM.”
BackgroundElsberger, B., Paravasthu, D. M., Tovey, S., & Edwards, J. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1096-8 · Cited by 15
“The non-receptor tyrosine kinase, c-Src, is overexpressed and highly activated in a number of human cancers including breast cancer and appears to show a significant relationship with cancer progression (Frame 2002; Yeatman 2004).”
BackgroundNovel Targeted Agents for the Treatment of Advanced Breast Cancer
Vega, M., Diaz-Canton, E. A., & Álvarez, R. H. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.45 · Cited by 15
Shakespeare, W. C., Wang, Y., Bohacek, R. S., Keenan, T., Sundaramoorthi, R., Metcalf, C., Dilauro, A., Roeloffzen, S., Liu, S., Saltmarsh, J., et al. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00615.x · Cited by 17
Weir, M. E., Mann, J. E., Corwin, T., Fulton, Z. W., Hao, J. M., Maniscalco, J. F., Kenney, M., Roque, K. M. R., Chapdelaine, E. F., Stelzl, U., et al. (2016) · FEBS Letters · doi:10.1002/1873-3468.12144 · Cited by 15
LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
Kim, Y. J., Hong, S., Sung, M., Park, M., Jung, K., Noh, K., Oh, D., Lee, M., Oh, E., Shin, Y. K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12657 · Cited by 18
“LYN is one of nine SFK family members, which participate in signal transduction and regulate various processes, including growth, survival, migration, and invasion, in cancer cells [4].”
BackgroundZhang, Q., Liu, S., Zheng, H., Wang, H., Luo, G., Zhang, X., Du, C., & Chen, J. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.146592 · Cited by 14
Thapa, N., Choi, S., Hedman, A. C., Tan, J. X., & Anderson, R. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512848 · Cited by 15
Wierstra, I. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.08.075 · Cited by 16
Dhruv, H., Whitsett, T. G., Jameson, N. M., Patel, F., Winkles, J. A., Berens, M. E., & Tran, N. L. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt289 · Cited by 17
“Despite the fact that Src is one of the oldest and most researched proto-oncogenes [46], specific signaling roles for individual SFKs in cancer are not well understood [16,34].”
BackgroundInfluentialSrc kinase activation by nitric oxide promotes resistance to anoikis in tumour cell lines
da Costa, P. E., Batista, W. L., de Moraes, M. S., Stern, A., & Monteiro, H. P. (2018) · Free Radical Research · doi:10.1080/10715762.2018.1455095 · Cited by 15
“Among all Src family kinases members, c-Src is frequently over expressed and/or aberrantly activated in a variety of epithelial and non-epithelial cancers [9].”
BackgroundNovel Tyrosine Kinase Targets in Urothelial Carcinoma
Torres-Jiménez, J., Albarrán, V., Pozas, J., Román, M. S., Esteban-Villarrubia, J., Carrato, A., Rosero, A., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020747 · Cited by 16
Abnormality of apico–basal polarity in adenocarcinoma
Onuma, K., & Inoue, M. (2022) · Cancer Science · doi:10.1111/cas.15549 · Cited by 12
Backe, S. J., Votra, S. D., Stokes, M. P., Sebestyén, E., Castelli, M., Torielli, L., Colombo, G., Woodford, M. R., Mollapour, M., & Bourboulia, D. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112539 · Cited by 13
FRET‐Based Activity Biosensors to Probe Compartmentalized Signaling
Gao, X., & Zhang, J. (2010) · ChemBioChem · doi:10.1002/cbic.200900594 · Cited by 16
v-Src-driven transformation is due to chromosome abnormalities but not Src-mediated growth signaling
Honda, T., Morii, M., Nakayama, Y., Suzuki, K., Yamaguchi, N., & Yamaguchi, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-19599-1 · Cited by 16
Yoon, H. J., Lee, S., Park, S. J., & Wu, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23964-5 · Cited by 13
Hussein, H. A. M., Okafor, I. B., Walker, L. R., Abdel-Raouf, U. M., & Akula, S. M. (2018) · Archives of Virology · doi:10.1007/s00705-018-3918-3 · Cited by 14
c‐Src promotes tumor progression through downregulation of microRNA‐129‐1‐3p
Okuzaki, D., Yamauchi, T., Mitani, F., Miyata, M., Ninomiya, Y., Watanabe, R., Akamatsu, H., & Oneyama, C. (2019) · Cancer Science · doi:10.1111/cas.14269 · Cited by 13
Epidermal hyperplasia and papillomatosis in mice with a keratinocyte-restricted deletion of csk
Honda, K., Sakaguchi, T., Sakai, K., Schmedt, C., Ramı́rez, Á., Jorcano, J. L., Tarakhovsky, A., Kamisoyama, H., & Sakai, T. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm112 · Cited by 14
“10 Csk-K5 keratinocytes significantly elevates SFK activity in vitro Since Csk is known as a cytoplasmic tyrosine kinase that negatively regulates the activity of SFKs through phosphorylation of their carboxy-terminal tyrosine [3], to confirm whether Csk indeed plays this role in keratinocytes, we next investigated th…”
BackgroundInfluentialWu, B., Sosa, A. C. B., Boschelli, D. H., Boschelli, F., Honores, E. E., Golas, J. M., Powell, D. W., & Wang, Y. D. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.015 · Cited by 14
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome
Diaz-Jimenez, A., Ramos, M., Helm, B., Chocarro, S., Frey, D. L., Agrawal, S., Somogyi, K., Klingmüller, U., Lu, J., & Sotillo, R. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101081 · Cited by 17
Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence
Quatrale, A. E., Petriella, D., Porcelli, L., Tommasi, S., Silvestris, N., Colucci, G., Angelo, A., & Azzariti, A. (2010) · Frontiers in bioscience · doi:10.2741/3834 · Cited by 15
“Activation of FAK stimulates also the cJUN aminoterminal kinase (JNK) signaling pathway, ultimately leading to increased expression of the matrix metalloproteinases MMP2 and MMP9 which promote the breakdown of the extracellular matrix (ECM) required for tumour invasion of surrounding tissues (30).”
BackgroundArray-based pharmacogenomics of molecular-targeted therapies in oncology
Sanoudou, D., Mountzios, G., Arvanitis, D., & Pectasides, D. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.53 · Cited by 14
Role and inhibition of Src signaling in the progression of liver cancer
Ren, H., Fang, J., Ding, X., & Chen, Q. (2016) · Open Life Sciences · doi:10.1515/biol-2016-0067 · Cited by 13
Lue, H.-W., Derrick, D. S., Rao, S. A. M., Gaest, A. V., Cheng, L. C., Podolak, J., Lawson, S., Xue, C., Garg, D., White, R. E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100267 · Cited by 19
“22 Consequently, upfront combinatorial drug therapies that block SRC and its key signaling partner(s) could be more effective than single-agent dasatinib.”
Role of Src Family Kinases in Prolactin Signaling
Martín-Pérez, J., García-Martínez, J. M., Sánchez-Bailón, M. P., Mayoral-Varo, V., & Calcabrini, A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-12114-7_7 · Cited by 15
“[29, 35, 91, 102].”
Hsu, K.-L., Fan, H.-J., Chen, Y., Huang, Y., Chen, C.-H., Wu, J., & Wang, S. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.016 · Cited by 13
Src siRNA prevents corticosteroid-associated osteoporosis in a rabbit model
Zheng, L., Wang, X., Cao, H., Chen, S., Huang, L., & Qin, L. (2015) · Bone · doi:10.1016/j.bone.2015.11.010 · Cited by 13
“Proto-oncogene tyrosine-protein kinase Src (also known as c-Src) participates in regulating a wide range of cell functions, including adhesion, motility, proliferation and survival [7,8].”
Chang, N., Lee, H. W., Jeong, D. E., Jeong, D. E., Song, H. J., Kim, S., Nam, D., Sung, H. H., Jeong, B. C., Jeon, S. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10539 · Cited by 13
“Despite playing a central role in multiple tumorigenic signaling networks of the SRC/FAK pathway [48, 49], SRC itself is rarely mutated in cancers [49].”
BackgroundSarcoma family kinase activity is required for cortical spreading depression
Bu, F., Wang, Y., Jiang, L., Ma, D., Quinn, J. P., & Wang, M. (2017) · Cephalalgia · doi:10.1177/0333102417748572 · Cited by 14
Song, H. E., Lee, Y., Kim, E., Cho, C. Y., Jung, O., Lee, D., Lee, E. G., Nam, S. H., Kang, M., Macalino, S. J. Y., et al. (2021) · Theranostics · doi:10.7150/thno.58739 · Cited by 13
“Transwell migration or invasion assay: Stable (TM4SF5-expressing) SNU449Tp cells were infected with adenoviruses expressing the control HA vector (Ad-TA) or various forms of FAK, including WT, an N-terminal deletion mutant (FAKΔ [1-100]), a kinase dead K454R mutant (KAK-KD), or the FERM domain”
Makino, Y., Tsuda, M., Ohba, Y., Nishihara, H., Sawa, H., Nagashima, K., & Tanaka, S. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0113-y · Cited by 17
“SFKs are non-receptor tyrosine kinases involved in various signalling pathways including cell proliferation, migration, adhesion, and angiogenesis [18, 19].”
BackgroundTisdale, E. J., Shisheva, A., & Artalejo, C. R. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.02.014 · Cited by 15
Kollmorgen, G., Bossenmaier, B., Niederfellner, G. J., Häring, H., & Lammers, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053050 · Cited by 13
“Full activation is obtained by phosphorylation of Y418 that stabilizes the activation loop of the kinase and thus the open conformation of the catalytic cleft (reviewed in [4,5]).”
BackgroundStegeman, H., Span, P. N., Rijken, P. F. J. W., Cockx, S. C., Wheeler, D. L., Iida, M., van der Kogel, A. J., Kaanders, J. H. A. M., & Bussink, J. (2013) · Translational Oncology · doi:10.1593/tlo.13259 · Cited by 16
“Src family kinases (SFKs) are non-receptor kinases involved in pathways that control cell division, motility, adhesion, angiogenesis, and survival [3,4].”
BackgroundDwivedi, M., Mejuch, T., Waldmann, H., & Winter, R. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706233 · Cited by 11
The Two Isoforms of Lyn Display Different Intramolecular Fuzzy Complexes with the SH3 Domain
Teixeira, J. M. C., Fuentes, H., Bielskutė, S., Gairí, M., Żerko, S., Koźmiński, W., & Pons, M. (2018) · Molecules · doi:10.3390/molecules23112731 · Cited by 12
“The members of the Src family of non-receptor tyrosine kinases (SFK) share a conserved architecture with three folded domains (SH1, which is the kinase domain; and SH2 and SH3 that are regulatory domains) and an N-terminal intrinsically disordered region that includes the SH4 and Unique domains [1].”
BackgroundInvadopodia, a Kingdom of Non-Receptor Tyrosine Kinases
Saha, T., & Gil-Henn, H. (2021) · Cells · doi:10.3390/cells10082037 · Cited by 12
“In addition to increasing tumor proliferation, Src plays a crucial role in promoting motility and invasion, functions that contribute to tumor progression and metastasis [24].”
BackgroundDawson, J. C., Munro, A. F., Macleod, K., Muir, M., Timpson, P., Williams, R. J., Frame, M. C., Brunton, V. G., & Carragher, N. O. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13151 · Cited by 13
“c-SRC (hereafter SRC) is the well known prototype of a large family of non-receptor tyrosine 48 kinases that promotes cancer cell migration, invasion, proliferation, and survival in different contexts 49 (2, 3).”
Metadata
- Authors
- Yeatman, T. J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J.
- ORCID
- Yeatman, Timothy J.
- Venue
- Nature Reviews Cancer
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 470-480
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2036988959
- Cited by
- 1,113
- References
- 115
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 20 · 2023: 43 · 2022: 43 · 2021: 46 · 2020: 44 · 2019: 39 · 2018: 49 · 2017: 44 · 2016: 69 · 2015: 56 · 2014: 72 · 2013: 79 · 2012: 73
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, non-receptor tyrosine kinase, cancer, metastasis, cell invasion, cell motility, cell proliferation, anticancer agents, tumor progression
- MeSH terms
- Antineoplastic Agents, Cell Division, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Phenotype, Gene Expression Regulation, Neoplastic, Genes, src, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.